[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2026-09-29-34":3},{"date":4,"filings":5,"has_more":123,"limit":124,"page":125,"total_count":126},"2026-09-29",[6,14,18,23,27,34,41,45,52,56,64,68,73,77,84,87,94,101,105,109,116],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"Quest Laboratories Limited","2026-09-29T08:45:27.254000","NSE","Manufacturing Expansion Update: Phase I Complete & Operational","6abb2d7af29e7b305fd938a0","QUESTLAB","*   Phase-I of the manufacturing expansion at the Pithampur facility is complete and has been operational since September 16, 2026.\n*   The new 12,000 sq. ft. building adds a finished goods warehouse, a blister packing line, and a state-of-the-art Quality Control section.\n*   For the Phase-II expansion (Injection Section), civil construction is finished. Machinery is expected by the end of December 2026.\n*   Trial runs for the new Injection Section are anticipated to begin in January-February 2027.",{"company_name":7,"filing_date":8,"filing_source":9,"headline":15,"id":16,"stock_code":12,"summary_text":17},"Key Update on Manufacturing Expansion","6abb2d90ed2d04f930d938b4","• Phase-I expansion is complete and operational as of September 16, 2026, adding a new 12,000 sq. ft. building.\n• The new facility includes a finished goods warehouse, a blister packing line, and a state-of-the-art Quality Control section.\n• Civil construction for the Phase-II (Injection Section) is complete, with clean room installation now underway.\n• For Phase-II, injection machines are expected by the end of December 2026, with trial runs anticipated in Jan-Feb 2027.",{"company_name":7,"filing_date":19,"filing_source":9,"headline":20,"id":21,"stock_code":12,"summary_text":22},"2026-09-29T08:45:27.182000","Order Book Position at ₹39.73 Crores","6abb2d72687ef99a874c98cf","• Total current order book stands at ₹39.73 Crores as of September 28, 2026.\n• New orders for the upcoming third quarter include ₹10.71 Crores from exports and ₹16.90 Crores from domestic sales.\n• The disclosure provides investors with visibility into the company's near-term revenue pipeline.",{"company_name":7,"filing_date":19,"filing_source":9,"headline":24,"id":25,"stock_code":12,"summary_text":26},"Order Book Reaches ₹39.73 Crores","6abb2d8fbb50beaad84c98cc","*   The company's current order book stands at \u003Cb>₹39.73 Crores\u003C\u002Fb> as of September 28, 2026.\n*   Confirmed orders for the upcoming third quarter total \u003Cb>₹27.61 Crores\u003C\u002Fb>.\n*   This includes ₹10.71 Crores in export orders and ₹16.90 Crores in domestic sales for the quarter.\n*   The update provides shareholders with enhanced visibility into the company's near-term revenue pipeline.",{"company_name":28,"filing_date":29,"filing_source":9,"headline":30,"id":31,"stock_code":32,"summary_text":33},"Aatmaj Healthcare Limited","2026-09-29T08:40:27.698000","Key Outcomes from the 12th Annual General Meeting","6abb2c4ef806575c31e9c18d","AATMAJ","*   The 12th Annual General Meeting (AGM) was successfully held on September 17, 2026, via video conference.\n*   Shareholders approved the adoption of the Audited Financial Statements for the financial year ended March 31, 2026.\n*   A key positive highlight is that both the Statutory and Secretarial Auditor reports for FY 2025-26 were clean, with no qualifications or observations.\n*   The Chairman addressed the members, providing an overview of the company's performance in FY 2025-26 and its future outlook.\n*   No new corporate actions such as dividends, buybacks, or mergers were announced in this filing.",{"company_name":35,"filing_date":36,"filing_source":9,"headline":37,"id":38,"stock_code":39,"summary_text":40},"Adani Energy Solutions Limited","2026-09-29T08:40:27.353000","Resolves Regulatory Matter with SEBI via Settlement Order","6abb2c47687ef99a874c98ce","ADANIENSOL","*   The company has received a Settlement Order from the Securities and Exchange Board of India (SEBI) regarding alleged past violations.\n*   A total settlement amount of **₹37.05 lakhs** was paid by the company and several current\u002Fformer directors, including Mr. Gautam S. Adani.\n*   The settlement was reached \"without admission or denial of the findings,\" resolving the regulatory proceedings.\n*   The company has stated that there is **no material financial impact** arising from this order.",{"company_name":35,"filing_date":36,"filing_source":9,"headline":42,"id":43,"stock_code":39,"summary_text":44},"Settles Regulatory Proceedings with SEBI","6abb2c61e625922c4ae4c56c","• The company and several directors (including Mr. Gautam S. Adani and Mr. Rajesh S. Adani) have settled proceedings with the Securities and Exchange Board of India (SEBI).\n• A total settlement amount of **INR 37,05,000** was paid to resolve the matter concerning alleged violations of listing and securities regulations.\n• The settlement was concluded \"without admission or denial of the findings of fact and conclusions of law.\"\n• The company states that there is **no material financial impact** from this order, and the settlement resolves the regulatory uncertainty associated with this matter.",{"company_name":46,"filing_date":47,"filing_source":9,"headline":48,"id":49,"stock_code":50,"summary_text":51},"Teamtech Formwork Solutions Limited","2026-09-29T08:30:28.769000","Key Highlights from the 8th Annual General Meeting","6abb29f5687ef99a874c98cd","TEAMTECH","*   The company shared a summary of its 8th AGM held on September 28, 2026, where all business items were transacted.\n*   **Financial Performance (FY 2025-26):**\n    *   Revenue from Operations: ₹53.66 Crores\n    *   Profit After Tax (PAT): ₹11.56 Crores (a significant growth from ₹7.83 Crores in the previous year).\n*   **Strategic Milestone:** The Chairman highlighted the successful listing of the company's shares on the NSE Emerge platform as a \"defining milestone\" for the year.\n*   **Next Steps:** Detailed voting results and the Scrutinizer's Report are pending and will be filed separately.",{"company_name":46,"filing_date":47,"filing_source":9,"headline":53,"id":54,"stock_code":50,"summary_text":55},"AGM Highlights: PAT Surges 47.6% & Successful NSE Emerge Listing","6abb2a10e625922c4ae4c56b","*   Profit After Tax (PAT) for FY 2025-26 grew by **47.6%** to **₹11.56 Crores**, up from ₹7.83 Crores in the previous year.\n*   Revenue from Operations for the year stood at **₹53.66 Crores**.\n*   The company highlighted its successful listing on the **SME Platform of the National Stock Exchange (NSE Emerge)** as a \"defining milestone\" of the year.\n*   The summary covers the proceedings of the 8th Annual General Meeting (AGM) held on September 28, 2026.\n*   The Statutory Auditors' Report for the financial year had no qualifications.",{"company_name":57,"filing_date":58,"filing_source":59,"headline":60,"id":61,"stock_code":62,"summary_text":63},"Heera Ispat Ltd","2026-09-29T08:05:28.918000","BSE","Trading Window Closed Ahead of Financial Results","6abb2412e625922c4ae4c56a","526967","*   The company has announced the closure of its trading window for dealing in its securities, effective from **October 01, 2026**.\n*   This is in anticipation of the announcement of the Unaudited Financial Results for the quarter and half-year ending September 30, 2026.\n*   The trading window will reopen **48 hours** after the financial results are declared to the stock exchange.\n*   The restriction applies to all Designated Persons, Connected Persons, and their immediate relatives.",{"company_name":57,"filing_date":58,"filing_source":59,"headline":65,"id":66,"stock_code":62,"summary_text":67},"Trading Window Closure Announced","6abb242bb10e13ced2e4c569","*   The trading window for dealing in the company's shares will be closed from **October 01, 2026**.\n*   This closure is in anticipation of the unaudited financial results for the quarter and half-year ending September 30, 2026.\n*   The trading restriction applies to all Designated Persons, Connected Persons, and their immediate relatives.\n*   The window will reopen **48 hours** after the financial results are publicly declared. The date of the results announcement will be shared later.",{"company_name":46,"filing_date":69,"filing_source":9,"headline":70,"id":71,"stock_code":50,"summary_text":72},"2026-09-29T07:50:27.267000","8th AGM Highlights: Strong Financials & Successful NSE Listing","6abb2095f29e7b305fd9389f","*   **Financial Performance (FY 2025-26):** The company reported Revenue from Operations of ₹ 53.66 Crores and a Profit After Tax (PAT) of ₹ 11.56 Crores.\n*   **Significant PAT Growth:** PAT showed strong growth, increasing from ₹ 7.83 Crores in the previous year to ₹ 11.56 Crores for FY 2025-26.\n*   **Key Milestone:** The Chairman highlighted the successful listing of the company's equity shares on the NSE Emerge platform as a defining achievement for the year.\n*   **AGM Proceedings:** All items of business as stated in the AGM notice were transacted. The consolidated voting results will be shared separately.\n*   **Management Outlook:** The Chairman expressed confidence in the company's future, aiming to build a stronger and more valuable enterprise.",{"company_name":46,"filing_date":69,"filing_source":9,"headline":74,"id":75,"stock_code":50,"summary_text":76},"AGM Highlights: PAT Jumps 47.64% & Successful NSE Listing","6abb20ae687ef99a874c98cc","*   \u003Cb>Profit After Tax (PAT) for FY26 grew by 47.64%\u003C\u002Fb> to ₹11.56 Crores, up from ₹7.83 Crores in the previous year.\n*   \u003Cb>Revenue from Operations\u003C\u002Fb> for the financial year ended March 31, 2026, stood at ₹53.66 Crores.\n*   The Chairman highlighted the \u003Cb>successful listing of the company's shares on the NSE Emerge platform\u003C\u002Fb> as a defining milestone for the year.\n*   This update summarizes the proceedings of the company's \u003Cb>8th Annual General Meeting (AGM)\u003C\u002Fb> held on September 28, 2026.\n*   All resolutions as per the AGM notice were transacted. The consolidated voting results will be disclosed separately.",{"company_name":78,"filing_date":79,"filing_source":59,"headline":80,"id":81,"stock_code":82,"summary_text":83},"Promax Power Ltd","2026-09-29T03:45:26.755000","Trading Window to Close Ahead of Financial Results","6abae721f29e7b305fd9389e","543375","• The company has announced the closure of its trading window for all designated persons, including promoters, directors, and key personnel.\n• The closure is in anticipation of the declaration of Unaudited Financial Results for the Half Year ended September 30, 2026.\n• The trading window will be closed from October 1, 2026, and will reopen 48 hours after the financial results are made public.",{"company_name":78,"filing_date":79,"filing_source":59,"headline":65,"id":85,"stock_code":82,"summary_text":86},"6abae739ed2d04f930d938aa","*   The trading window for Designated Persons will be closed starting **October 1, 2026**.\n*   This closure is in anticipation of the Unaudited Financial Results for the half-year ending September 30, 2026.\n*   The trading window will reopen 48 hours after the financial results are publicly declared.\n*   This is a standard compliance measure under SEBI regulations to prevent insider trading.",{"company_name":88,"filing_date":89,"filing_source":9,"headline":90,"id":91,"stock_code":92,"summary_text":93},"Adani Power Limited","2026-09-29T02:05:27.011000","Adani Power Settles Regulatory Case with SEBI","6abad241b0530a2ce74c98cc","ADANIPOWER","*   Adani Power and its directors have resolved proceedings with the Securities and Exchange Board of India (SEBI) by paying a settlement amount of **INR 37,05,000**.\n*   The settlement resolves alleged violations of various securities laws, including rules on minimum public shareholding and listing agreements.\n*   This resolution was reached without any admission or denial of guilt by the company or the directors involved.\n*   The company has stated that there is no material financial impact from this order, which removes a regulatory uncertainty for stakeholders.",{"company_name":95,"filing_date":96,"filing_source":9,"headline":97,"id":98,"stock_code":99,"summary_text":100},"Prime Focus Limited","2026-09-29T00:50:47.095000","Strong FY26 Growth & $150M Fundraise for AI Arm","6abad1f4572946bf51e9c149","PFOCUS","*   Reports strong FY26 results with 30% revenue growth to ₹4,676 Cr and 81% EBITDA growth to ₹1,423 Cr, returning to a net profit of ₹301 Cr from a loss in the previous year.\n*   Announces a **$150M fundraise** for its AI subsidiary, **Brahma AI**, at a **$2B valuation**. Post-deal, PFL will retain a 65.67% economic interest.\n*   Maintains a robust contracted order book of over **$600M** as of June 2026.\n*   Highlights key upcoming projects, including the major studio production **'Ramayana'**, scheduled for release in October 2026.",{"company_name":95,"filing_date":96,"filing_source":9,"headline":102,"id":103,"stock_code":99,"summary_text":104},"Unlocks Value: AI Arm Brahma AI Valued at $2B","6abad1ff7cb10111b4d9389e","• AI subsidiary Brahma AI raises $150M at a $2B post-money valuation. PFL's voting interest will reduce to 24.99%, making it an associate, while retaining a 65.67% economic interest.\n• FY26 financials show a strong turnaround: Revenue grew 30% to ₹4,676 Cr, EBITDA surged 81% to ₹1,423 Cr, and Net Profit reached ₹301 Cr (vs. a ₹458 Cr loss in FY25).\n• Prime Focus Studios' investment in \"The Garfield Movie\" yielded an ROI of over 50%, validating its risk-hedged co-production model.\n• Company highlights a strong outlook with a robust order book of $600M+ as of June 30, 2026, driven by a resurgence in content creation post-Hollywood strikes.",{"company_name":95,"filing_date":96,"filing_source":9,"headline":106,"id":107,"stock_code":99,"summary_text":108},"AI Arm Valued at $2B; Strong Post-Strike Recovery","6abad2c3e625922c4ae4c569","*   \u003Cb>Brahma AI Fundraise:\u003C\u002Fb> Raised \u003Cb>$150M\u003C\u002Fb> at a \u003Cb>$2B valuation\u003C\u002Fb>, led by Multiples. PFL's voting interest will reduce to 24.99%, but it will retain a 65.67% economic interest.\n*   \u003Cb>Strong Financial Performance:\u003C\u002Fb> FY26 revenue grew to \u003Cb>₹4,676 Cr\u003C\u002Fb> with an EBITDA margin of 30.4%. Q1'FY27 revenue grew 24% YoY to \u003Cb>₹1,267 Cr\u003C\u002Fb>, showing a strong resurgence post-Hollywood strikes.\n*   \u003Cb>Strategic Initiatives:\u003C\u002Fb> Pursuing a risk-hedged content investment strategy with major upcoming releases like \"Ramayana\" (Oct 2026) and \"The Garfield Movie\".\n*   \u003Cb>Acquisition:\u003C\u002Fb> Acquired a majority stake in Spanish animation studio 'Anima Kitchent' to expand animation production.\n*   \u003Cb>Key Monitorables:\u003C\u002Fb> Management noted elevated Net Working Capital (220 days in FY26) and Net Debt of ₹4,376 Cr (as of Q1'FY27) as key areas of focus.",{"company_name":110,"filing_date":111,"filing_source":9,"headline":112,"id":113,"stock_code":114,"summary_text":115},"Adani Ports and Special Economic Zone Limited","2026-09-29T00:35:27.291000","SEBI Settlement Order Update","6abacb2419297ecafd4535fe","ADANIPORTS","*   The company has received a Settlement Order from the Securities and Exchange Board of India (SEBI) regarding applications filed by the company, two current directors (Mr. Gautam S. Adani & Mr. Rajesh S. Adani), and three former directors.\n*   A total settlement amount of **₹37,05,000** was paid to resolve proceedings for alleged violations of various securities regulations.\n*   The settlement was concluded \"without admission or denial of the findings of fact and conclusions of law.\"\n*   The company has stated that there is **no material financial impact** arising from this order.",{"company_name":117,"filing_date":118,"filing_source":9,"headline":119,"id":120,"stock_code":121,"summary_text":122},"Anupam Rasayan India Limited","2026-09-29T00:00:28.711000","Acquires Controlling Stake in Bliss GVS Pharma","6abac047206bcb25c247424c","ANURAS","*   Anupam Rasayan has successfully acquired a controlling **50.07%** stake in **Bliss GVS Pharma Limited**, becoming its new promoter.\n*   The acquisition was completed through a Share Purchase Agreement (47.95% stake) and an on-market transaction (2.12% stake) on September 28, 2026.\n*   This is a strategic move to create an integrated pharmaceutical platform, spanning from raw materials (KSMs) to finished dosage formulations.\n*   The company aims to combine its advanced chemistry capabilities with Bliss GVS's formulation expertise and strong international footprint to unlock synergies and drive growth.",false,100,34,3321]